Lilly grants single-patient compassionate-use access to retatrutide
TL;DR Summary
Lilly has granted compassionate-use access to its obesity drug candidate retatrutide for a single patient, according to STAT’s exclusive reporting; The Readout also covers Pfizer’s lung-cancer trial results and other biotech news.
Topics:business#biotech#compassionate-use#lilly#obesity-treatment#pfizer-lung-cancer-trial#retatrutide
- Lilly’s retatrutide has been offered to a single person via ‘compassionate use’ program statnews.com
- Eli Lilly gave extraordinary obesity drug access to a 79-year-old patient. Who was it? statnews.com
- Did Trump Get Special Access to Retatrutide? Mother Jones
- White House Cornered on Identity of Patient, 79, Given Special Weight Loss Drug The Daily Beast
- White House Denies Trump Got Unapproved Obesity Drug MedPage Today
Reading Insights
Total Reads
1
Unique Readers
2
Time Saved
2 min
vs 3 min read
Condensed
93%
427 → 32 words
Want the full story? Read the original article
Read on statnews.com